Search clinical trials for: Recombinant Granulocyte Colony-Stimulating Factor

Total 1902 results

Takeda
Baxalta Innovations GmbH, now part of Shire

Completed

rVWF IN PROPHYLAXIS

Von Willebrand Disease

United States, Spain, Italy, Turkey, Germany, Russian Federation, Netherlands, France, Canada
Fred Hutchinson Cancer Center
Jazz Pharmaceuticals

Recruiting

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

Acute Myeloid Leukemia | Myeloid Neoplasm

United States
Novo Nordisk A/S

Completed

Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725 (mentor™2)

Congenital Bleeding Disorder | Congenital FXIII Deficiency

France, United States, Israel, Spain, Switzerland, Germany, Canada, Japan, United Kingdom, Italy, Finland, Austria
Novo Nordisk A/S

Completed

Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects

Healthy | Congenital Bleeding Disorder | Congenital FXIII Deficiency

United Kingdom
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B

Hemophilia B
University of Virginia

Not yet recruiting

Recombinant vWF Concentrate and ECMO

Bleeding Disorder

United States
Novo Nordisk A/S

Completed

Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study (mentor™6)

Congenital Bleeding Disorder | Congenital FXIII Deficiency

Spain, United States, Canada, Italy, United Kingdom, Hungary
Novo Nordisk A/S

Completed

Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency (mentor™5)

Congenital Bleeding Disorder | Congenital FXIII Deficiency

United Kingdom, Israel, United States
Washington University School of Medicine
National Cancer Institute (NCI); National Institutes of Health (NIH); ImmunityBio... and other collaborators

Recruiting

Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation

Acute Myeloid Leukemia

United States
Pfizer

Completed

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma | Plasma Cell Leukemia

United States
Masonic Cancer Center, University of Minnesota

Terminated

Stem Cell Transplantation for Hematological Malignancies

AML | MDS | Leukemia, Lymphocytic, Acute

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia

Leukemia

United States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma

Lymphoma

United States, Canada, Australia, Puerto Rico, Switzerland
Washington University School of Medicine

Completed

Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML (CLAG ATRA AML)

Leukemia, Myeloid, Acute

United States
Instituto Bernabeu

Unknown

Efficacy of Urinary Vs Recombinant FSH in Oocyte Donors Based on Receptor N680S FSH Gene Polymorphism (Genodon Trial) (GENODON)

Reproductive Techniques, Assisted

Spain
Baxalta now part of Shire

Completed

Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS (SPACE)

Hemophilia A | Hemophilia B

United States
Bayer

Completed

Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A (Leopold I)

Hemophilia A | Blood Coagulation Disorders

Spain, Taiwan, Austria, United States, Germany, Thailand, United Kingdom, Italy, Turkey, Croatia, Serbia, Poland, Israel, Sweden, Indonesia, Argentina, Norway, South Africa, India, Hong Kong, Denmark, Pakistan
Universiti Sains Malaysia

Completed

Recombinant Activated Factor VII in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia

Massive Hemorrhage | Massive Blood Loss | Massive Blood Transfusion; Thrombocytopenia

Malaysia
Novo Nordisk A/S

Completed

Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury

Trauma | Acquired Bleeding Disorder

United States, Canada
Novo Nordisk A/S

Completed

Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects

Healthy | Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Acquired Bleeding Disorder | Acquired Haemophilia | Congenital FVII Deficiency | Glanzmann's Disease

France
Novo Nordisk A/S

Completed

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

Acquired Bleeding Disorder | Intracerebral Haemorrhage

Spain, Sweden, Singapore, Norway, Italy, Switzerland, Australia, Austria, Belgium, Canada, Denmark, Finland, Germany, Netherlands, United Kingdom
Novo Nordisk A/S

Completed

Dose Response to Recombinant Factor VIIa When Administered for Bleed

Healthy | Congenital Bleeding Disorder

United States
Novo Nordisk A/S

Completed

Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

France, Israel, Germany
Pfizer

Completed

Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B

Hemophilia B

United States, Spain, Croatia, Serbia, Russian Federation, Canada, Hungary, Italy, Romania
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A

Hemophilia A

China
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

Acquired Hemophilia A

United States, Italy, United Kingdom, Germany, Austria, Netherlands, France
Shenyang Sunshine Pharmaceutical Co., LTD.

Unknown

Study of rESP Injection for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis

Chronic Renal Failure With Hemodialysis

China
Novo Nordisk A/S

Completed

Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis

Other Haemostasis Disorder | Haemorrhagic Cystitis

United States
Novo Nordisk A/S

Terminated

Use of Activated Recombinant Human Factor VII in Cardiac Surgery

Acquired Bleeding Disorder | Cardiac Surgery Requiring Cardiopulmonary Bypass

United States, Spain, Germany, Sweden, United Kingdom, Argentina, Italy, Brazil, Denmark, France, India, Malaysia, Singapore, South Africa
Novo Nordisk A/S

Completed

High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

France, United Kingdom, Spain, Israel, Poland, Turkey, Hungary
Novo Nordisk A/S

Completed

Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency

Congenital Bleeding Disorder | Congenital FVII Deficiency

Japan
Novo Nordisk A/S

Terminated

A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis

Inflammation | Ulcerative Colitis

Poland, Croatia, Denmark, Bulgaria, Hungary, Ukraine, Russian Federation
Medexus Pharma, Inc.

Terminated

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B

Hemophilia B

United States, United Kingdom, India
University of Cincinnati
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

The Spot Sign for Predicting and Treating ICH Growth Study (STOP-IT)

Intracerebral Hemorrhage

United States, Canada
Grifols Biologicals, LLC

Completed

Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B

Hemophilia B

Bulgaria
Novo Nordisk A/S

Completed

Use of NovoSeven® in Active Variceal Bleeding

Cirrhosis | Acquired Bleeding Disorder

Germany, United Kingdom, Spain, Taiwan, France, Italy, Austria, Czech Republic, Poland, Denmark, Finland, Hong Kong
Novo Nordisk A/S

Completed

Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury

Trauma | Acquired Bleeding Disorder

India, Spain, Canada, Finland, Germany, Israel, Italy, Netherlands, Singapore, Switzerland, Taiwan
Pfizer

Completed

Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B

Hemophilia B

Korea, Republic of
Novo Nordisk A/S

Withdrawn

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma

Trauma | Acquired Bleeding Disorder

United States
Sunshine Lake Pharma Co., Ltd.

Recruiting

HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

Leukemia, Acute Myeloid (AML)

China
National Heart, Lung, and Blood Institute (NHLBI)
National Cancer Institute (NCI); National Marrow Donor Program; Blood and Marrow...

Completed

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

Multiple Myeloma

United States
Sinocelltech Ltd.

Unknown

Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A

Hemophilia A

China
The Hospital for Sick Children
Terry Fox Foundation

Active, not recruiting

Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma

Retinoblastoma

Canada, Chile, India, Singapore
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Lymphoma

United States
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

Acquired Hemophilia A

United States
Boston Medical Center

Completed

Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma

United States
Sanofi

Completed

Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer (PROSPECTA)

Prostate Cancer

Brazil
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Lymphoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma | Recurrent Cervical Carcinoma | Cervical Small Cell Carcinoma | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical Cancer

United States
Medexus Pharma, Inc.

Completed

Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B

Hemophilia B

Turkey, Brazil, Georgia, Moldova, Republic of, South Africa, Ukraine

Search clinical trials for: Recombinant Granulocyte Colony-Stimulating Factor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations